MedTrace Logo

PREP (Pre-Exposure Prophylaxis) of COVID-19

NCT05461378 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2024-07-15

No results posted yet for this study

Summary

This is a study of immunocompromised individuals who have received or plan to receive a drug called EVUSHELD. This study is looking at any serious adverse events that might happen after receiving EVUSHELD, the levels of EVUSHELD in participant's blood, blood antibody levels, neutralizing antibodies against SARS-CoV-2 (the virus that causes COVID-19), and other blood responses related to the immune system and COVID-19. Investigators are collecting blood and may also collect other samples such as nose swabs, oral swabs, or saliva.

Conditions

Interventions

DRUG

Evusheld

Participants who have received or plan to receive Evusheld.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Ghady Haidar

    lead OTHER

Principal Investigators

  • Ghady Haidar, MD · University of Pittsburgh and UPMC

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-26
Primary Completion
2024-01-29
Completion
2024-01-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461378 on ClinicalTrials.gov